Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 14, 2006; 12(38): 6115-6123
Published online Oct 14, 2006. doi: 10.3748/wjg.v12.i38.6115
Published online Oct 14, 2006. doi: 10.3748/wjg.v12.i38.6115
Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete?
Ad A van Bodegraven, Section of Inflammatory Bowel Diseases, VU University medical centre, Amsterdam, The Netherlands
Chris JJ Mulder, Department of Gastroenterology, VU University medical centre, Amsterdam, The Netherlands
Supported by research grants from Astrazeneca (Zoetermeer, The Netherlands), Ferring BV (Hoofddorp, The Netherlands), P and G Pharmaceuticals (Cincinnati, United States), ALTANA Pharma BV (Hoofddorp, The Netherlands), and Tramedico BV (Weesp, The Netherlands), Falk Company (Freiburg, Germany), and Ferring International (Copenhagen, Denmark)
Correspondence to: Ad van Bodegraven, Department of Gastroenterology, VU University medical centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands. v.bodegraven@vumc.nl
Telephone: +31-20-4440613 Fax: +31-20-4440554
Received: November 8, 2005
Revised: November 28, 2005
Accepted: February 20, 2006
Published online: October 14, 2006
Revised: November 28, 2005
Accepted: February 20, 2006
Published online: October 14, 2006
Core Tip